Late-Breaking Science – Scientific Sessions 2025

LBS.01 Groundbreaking Trials in Cardiometabolic Therapeutics

Saturday, November 08, 2025, 8:30 AM

• DR10624, a First-In-Class, FGF21 Receptor/Glucagon Receptor/GLP-1 Receptor Triple Agonist, Rapidly and Significantly Reduced Triglycerides, Atherogenic Lipids, and Liver Fat in Patients With Severe Hypertriglyceridemia: Primary Results From a Randomized Phase 2 Trial
• 4391485 - Olezarsen in Patients with Severe Hypertriglyceridemia: The CORE-TIMI 72a and CORE2-TIMI 72b Trials
• First-in-Human Phase 1 Clinical Trial of a CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
• VESALIUS-CV – Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke: Primary Results of the VESALIUS-CV trial

LBS.02 Dilemmas in antithrombotic therapy in AF care post procedures

Saturday, November 08, 2025, 1:30 PM

• ADAPT AF-DES – Appropriate Duration of Antiplatelet and Thrombotic Strategy after 12 Months in Patients with Atrial Fibrillation Treated with Drug-Eluting Stents  
• OPTIMA-AF Trial – Short Dual Antithrombotic Therapy after PCI in Patients with Atrial Fibrillation: OPTIMA-AF trial
• CLOSURE-AF – Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy
• OCEAN – The Need for Ongoing Oral Anticoagulation in Patients with Clinical Stroke Risk Factors After Successful Catheter Ablation of Atrial Fibrillation: The OCEAN Randomized Trial

LBS.03 Cutting Edge Valve and Coronary Trials

Saturday, November 08, 2025, 3:15 PM

• RECOVERY – Early Surgery Versus Conservative Management for Asymptomatic Severe Aortic Stenosis: Final Outcomes of the RECOVERY Trial *
• ABLATION – Biatrial versus Left Atrial Ablation during Mitral Valve Surgery for Persistent Atrial Fibrillation in Rheumatic Heart Disease
• FAVOR 4-QVAS –Angiography-derived FFR-Guided Coronary Artery Bypass Grafting for Patients undergoing Valve Surgery with Concomitant Coronary Artery Disease : a Randomized Trial *
• TOP – Liberal or Restrictive Transfusion Strategy after General and Vascular Surgery: The Transfusion Trigger after Major Operations in High Cardiac Risk Patients Trial 

LBS.04 Cardiometabolic and Lifestyle Interventions for AF

Sunday, November 09, 2025, 8:00 AM

• DARE-HF – Dapagliflozin to Reduce Atrial Fibrillation Burden After Catheter Ablation for Atrial Fibrillation in Patients Without Diabetes or Heart Failure: The DARE-AF Randomized Clinical Trial *
• META-AF – Metformin as an Adjunctive Therapy to Catheter Ablation of Atrial Fibrillation
• DECAF – The Does Eliminating Coffee Avoid Fibrillation (DECAF) Trial

LBS.05 Practice Changing Trials in Blood Pressure Control 

Sunday, November 09, 2025, 3:30 PM

• SSTT (See Sodium To Treat) – Oral KCl Supplementation Safely Reduces Body Na+ Surplus and Blood Pressure in Patients with Arterial Hypertension
• BETTER-BP– Primary results of the Behavioral Economics Trial to Test Effective Regulation of Blood Pressure
• GOFRESH – DASH-Patterned Groceries Reduce Blood Pressure: Results from the GoFresh Randomized Clinical Trial
• Healthy Family Program – A multifaceted family intervention for blood pressure management in rural China: an open label, parallel group, cluster randomized trial *

LBS.06 Approaches to Ischemic Heart Disease Before During and After Hospitalization

Monday, November 10, 2025, 8:00 AM

• CELEBRATE – Prehospital treatment with Disaggprotm (Zalunfiban) in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention: Final results of the CELEBRATE trial
• TUXEDO-2 – Ticagrelor versus Prasugrel in Patients with Diabetes Mellitus and Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Randomized Comparison from the TUXEDO-2 Trial
• DAPT-MVD – Efficacy and Safety of Extended Dual Antiplatelet Therapy in Stable Patients With Multivessel Coronary Artery Disease Undergoing Drug-Eluting Stent Implantation (DAPT-MVD): An Investigator-Initiated, Multicenter, Randomized, Open-Label, Assessor-Masked, Superiority Trial
• CorCMR – Non-Invasive Endotyping in Patients with Angina and No Obstructive Coronary Artery Disease: A Randomized, Controlled Trial

LBS.07 Recipes for Success in Heart Failure

Monday, November 10, 2025, 9:45 AM

• POLY-HF – A Polypill Strategy for Heart Failure with Reduced Ejection Fraction: The POLY-HF Trial
• CAVIAR– Cardiac Allograft Vasculopathy Inhibition with AliRocumab: The CAVIAR Trial
• FOOD-HF– Examining the Impact of Medically Tailored Meals vs Produce Supplements Delivered Conditionally vs Unconditionally on Heart Failure Readmissions and Emergency Department Visits: A Randomized Clinical Trial
• SURPASS-CVOT – Once-weekly Tirzepatide versus Dulaglutide for Heart Failure Outcomes in Patients with Type 2 Diabetes, ASCVD, and History of Heart Failure (pre-specified analysis of the SURPASS-CVOT Randomized Clinical Trial)

_{* Accepted, not confirmed}

Back to Top

HCMS.FS Featured Science: HCMS

Friday, November 07, 2025, 6:00 PM

• Effect of Mavacamten on Measures of Cardiopulmonary Exercise Testing: An Analysis of the ODYSSEY-HCM Randomized Trial
• Polygenic Risk Enhances Penetrance and Prognosis in Hypertrophic Cardiomyopathy: Insights from a US-based Multi-Ancestry Cohort
• MAPLE-HCM - Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy
• ODYSSEY-HCM - Effect of selected baseline characteristics and exposure on efficacy and safety of mavacamten: A Post-Hoc Analysis from the ODYSSEY trial 

FS.01 Arteries and Veins in Trouble: VTE and PAD

Saturday, November 08, 2025, 9:45 AM

• ROXI – Two Mechanistically Distinct Factor XI Antibodies, REGN9933 and REGN7508, for the Prevention of Venous Thromboembolism After Knee Arthroplasty: the ROXI-VTE-I and ROXI-VTE-II trials 
• PERMET – Metformin for walking impairment in peripheral artery disease: The PERMET Randomized Clinical Trial. 
• Foot-PAD – A Double-Blind, Randomized Placebo-Controlled Trial to determine the effect of a 12-Week Program of Footplate Neuromuscular Electrical Stimulation on Walking Capacity in Patients with Peripheral Artery Disease
• DART – DDCI-01 in Pulmonary Arterial Hypertension: A Multicenter Phase IIa Randomized Active-Controlled Trial
• SATISFY-JP Trial – Satralizumab, an Anti-Interleukin-6 Receptor Antibody, for Pulmonary Arterial Hypertension with an Activated Immune-Responsive Phenotype: Primary Results from the Phase II Trial 
• PULSAR, STELLAR, ZENITH - Effect of Sotatercept on Mortality and Major Morbidity Outcomes in Patients with Pulmonary Arterial Hypertension: Pooled Analysis of the PULSAR, STELLAR, and ZENITH Trials
• RESCUE-PTTM – Efficacy and Safety of Imatinib Therapy Administered in Patients with Pulmonary Tumor Thrombotic Microangiopathy (PTTM): A Prospective, Multi-Center Exploratory Clinical Trial

FS.02 From Madrid to Mardi Gras: Heart Failure Trials on Parade

Saturday, November 08, 2025, 1:30 PM

• Get with the Guidelines Hospital Participation and its Impact on GDMT and HF Outcomes using an Interrupted Time Series Analysis *
• DIGIT-HF – Efficacy and safety of Digitoxin in heart failure with reduced ejection fraction according to age: Insights from DIGIT-HF *
• MAPLE-HCM – Clinical Responses to Aficamten Monotherapy Compared with Metoprolol for Obstructive Hypertrophic Cardiomyopathy Outcomes and Disease Burden: MAPLE-HCM Responder Analysis
• DAPA ACT HF-TIMI 68 – Blood Pressure and Symptomatic Hypotension with Dapagliflozin vs. Placebo in Patients Hospitalized with Heart Failure
• SOTA-P-CARDIA Trial (ATRU-V) – A Randomized Trial of Sotagliflozin in HFpEF patients without diabetes *
• SURPASS-CVOT – Effects of Sodium-Glucose Cotransporter-2 Inhibitor Use on Major Adverse Cardiovascular Events in Participants With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Treated With Tirzepatide Versus Dulaglutide *

FS.03 Trials and Deployments of Artificial Intelligence in Cardiology

Saturday, November 08, 2025, 3:15 PM

• DETECT-HF – Multicenter Clinical Study of Remote Speech Analysis to Detect Worsening Heart Failure: Results of the Pivotal DETECT-HF Trial *
• DAMSUN-HF – Prospective Validation and Real-World Implementation of an AI-Enabled Digital Stethoscope for Detecting Systolic Dysfunction in Low-Resource Settings
• Improved Identification of Near-Term Heart Failure Risk in Pooled Cohort Studies Using ECG-AI and PREVENT-HF
• ECG2Stroke – ECG deep learning model accurately predicts ischemic stroke risk *
• Accuracy of cardiologist reporting of severe aortic stenosis and its impact on clinical management: Insights from decision-support artificial intelligence applied to 28,491 men and women undergoing echocardiography *

FS.04 Biological and Pragmatic Interventions in Heart Failure: From Present to Future

Sunday, November 09, 2025, 8:00 AM

• ANSWER-HF – A Randomized Controlled Trial of Sacubitril/Valsartan Versus Enalapril in Patients with Chronic Chagas Cardiomyopathy and Reduced Ejection Fraction
• DAPA-EAT – Dapagliflozin Reduces Epicardial Adipose Tissue and Myocardial Fibrosis in Subclinical Heart Failure: The DAPA-EAT Trial
• MAPLE-HCM – Effect of Aficamten versus Metoprolol Monotherapy on Biomarkers in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Trial
• First-in-Human Gene Therapy Trial for Patients with Heart Failure with preserved Ejection Fraction (HFpEF) MUSIC-HFpEF: Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction *
• BioVAT-HF DZHK20 – Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure - BioVAT-HF-DZHK20 – Phase II Interim Data Report *
• COPILOT HF – Main Results of the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure (COPILOT-HF) Program – A Pragmatic Randomized Study 

FS.05 Medical and Interventional Advances in Coronary Artery Disease

Sunday, November 09, 2025, 9:15 AM

• TARGET-D – A Randomized Clinical Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Acute Coronary Syndrome Patients: The TARGET-D Trial
• ICare-FASTER – Improving Care by Faster Risk-Stratification with High-Sensitivity Point-of-Care Troponin in Patients in the Emergency Department: A Stepped-Wedge Cluster Randomised Trial
• Heart Matters – The effectiveness of heart attack education in regions at highest-risk – the Heart Matters Stepped-Wedge Randomized Control Trial
• iSENSE-ACS – Infrared Sensor Evaluation for Noninvasive Screening and Early triage in Acute Coronary Syndromes: The iSENSE-ACS Multicenter Study
• CRTC – An individual patient data meta-analysis of complete versus culprit-lesion only revascularization for acute myocardial infarction involving >8,800 individuals: The Complete Revascularization Trialists’ Collaboration (Complete Revascularization Trialist's Collaboration (CRTC)) *
• FAMOUS – Long-term follow-up of patients with multivessel coronary artery disease – comparison between Functional, Anatomical, or Medical Only-based Evaluation to Prevent Cardiovascular Events – The FAMOUS Trial
• Beta-Blocker Therapy After Myocardial Infarction in Patients with Preserved Left Ventricular Ejection Fraction: An Individual Patient Data Meta-Analysis of Randomized Controlled Trials (REBOOT, REDUCE-AMI, BETAMI, DANBLOCK, CAPITAL-RCT)
• NEO-MINDSET – Early Aspirin Withdrawal after Percutaneous Coronary Intervention in Acute Coronary Syndromes With and Without ST-Segment Elevation: Results from the NEO-MINDSET trial

FS.06 Pan Vascular Interventions: Anatomy and Interventions Across Various Vascular Beds

Sunday, November 09, 2025, 11:50 AM

• J-BPA – Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: A Nationwide Prospective Multicenter Registry in Japan
• FAIR – Fractional Flow Reserve-guided Renal Artery Stenting in Atherosclerotic Renovascular Hypertension: 1 Year Results of the FAIR Randomized Trial
• COACT – Coronary Angiography After Cardiac Arrest Without ST-Segment Elevation: Five-Year Outcomes *
• OPTIMAL – Prospective, multicenter, open-label, randomized controlled trial of deferred stenting versus prompt stenting in acute occlusion of left main coronary artery: Primary outcomes of the OPTIMAL trial *
• SCAPIS – Coronary CT Angiography in Prediction of Coronary Events *
• MUSHY PEAS – Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction *
• CONFIRM2 – Risk stratification by AI-guided CT coronary atherosclerosis quantification alongside the clinical likelihood of obstructive stenosis. (CONFIRM2)

FS.07 Emerging Opportunities for Managing Cardiometabolic Syndrome

Sunday, November 09, 2025, 3:15 PM

• SPRINT – Arterial Stiffness Mechanisms and Orthostatic Hypotension in The Systolic Blood Pressure Intervention Trial *
• KARDIA-3 – A randomized trial of zilebesiran versus placebo on top of standard care for patients with hypertension and established cardiovascular disease or high cardiovascular risk with or without chronic kidney disease
• Bax24 – Effect of Baxdrostat on 24-Hour Average Ambulatory Blood Pressure in Patients with Resistant Hypertension: The Bax24 Trial
• SURPASS-CVOT – Once-weekly tirzepatide versus dulaglutide on major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease 
• TIRZSEMA-CVOT – Cardiovascular Outcomes for Tirzepatide and Semaglutide: A RCT-DUPLICATE Initiative
• CORALreef HeFH – Enlicitide, an oral PCSK9 inhibitor, in participants with heterozygous familial hypercholesterolemia: a double-blind, Phase 3, randomized placebo-controlled trial  
• LIBerate-OLE – Long-term Efficacy and Safety of Lerodalcibep in the Open-label 72-week Extension Study of Subjects Previously on Inclisiran or Lerodalcibep in the LIBerate-VI Trial (LIBerate-OLE)
• ELM – Lifestyle intervention for sustained remission of metabolic syndrome (ELM: Enhanced Lifestyles in the Metabolic Syndrome)

FS.08 Featured Science in EP

Monday, November 10, 2025, 8:00 AM

• PFA-SHAM – Pulsed Field Ablation versus Sham Ablation to Treat Atrial Fibrillation
• MANIFEST-US – Multicenter Study on the Safety of Pulsed Field Ablation in the United States
• Strength-Based Exercise is Not Associated with Risk of Ventricular Arrhythmia in Arrhythmogenic Cardiomyopathy – Towards Safer Exercise Options
• Artificial Intelligence Analysis of the 12-lead ECG and Clinical Factors to Predict Out-of-Hospital Cardiac Arrest
• ACE-PAS – Primary Results from the Post Approval Study of a Next Generation Wearable Cardioverter Defibrillator System: the ACE-PAS Trial
• FLECA-ED – Efficacy and safety of flecainide compared to amiodarone for atrial fibrillation cardioversion in patients with Coronary Artery Disease and preserved ejection fraction

FS.09 Influenza and COVID Science

Monday, November 10, 2025, 1:30 PM

• High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes: The FLUNITY-HD Pooled Analysis *
• KP-VACCINATE - Impact of Cardiovascular-Focused Messaging to Improve Influenza Vaccination on Cardiovascular-Kidney-Metabolic Care Patterns and Clinical Outcomes: Insights from the KP VACCINATE Megatrial
• DAN-GAL-FLU - Effectiveness of High-Dose vs. Standard-Dose Inactivated Influenza Vaccine in Individuals with and without Atherosclerotic Cardiovascular Disease: A Pooled FLUNITY-HD Trial Analysis (DAN-GAL-FLU (DANFLU-2 and GALFLU))
• NUDGE-FLU-CHRONIC - Influenza vaccination and risk of cardiovascular events: An instrumental variable analysis of >600,000 participants from the NUDGE-FLU-CHRONIC 1 and 2 trials
• CISCO-21 - Resistance Exercise Therapy After COVID-19 Infection: a Randomized, Controlled Trial *

FS.10 Rewriting the Code for Cardiac Amyloid: Novel Identification, Treatment, and Cure

Monday, November 10, 2025, 1:30 PM

• AI-SCREEN-CA - Artificial Intelligence-based Software for Checking REal-world Echocardiography to ideNtify hidden Cardiac Amyloidosis: AI-SCREEN-CA *
• Improving Detection of Transthyretin Cardiac Amyloidosis with AI: A Single-Arm Multicenter Trial *
• ATTR-CM - Primary results from the phase 2 randomized, placebo controlled, blinded trial of the monoclonal antibody coramitug in transthyretin amyloid cardiomyopathy *
• Updated Phase 1 Clinical Trial Outcomes of CRISPR Gene Editing With Nexiguran Ziclumeran In Patients With Transthyretin Amyloidosis With Cardiomyopathy

FS.11 Lipid Therapies: Translation to Implementation

Monday, November 10, 2025, 3:15 PM

• SHR-1918, an Angiopoietin-Like 3 Antibody, in Patients With Suboptimally Controlled Hyperlipidemia *
• Dose-Dependent and Sustained Reduction in Lipoprotein(a) levels after single-dose of Kylo-11, a LPA-targeted Small Interfering RNA, in Healthy Volunteers: A First-in-Human Phase I Study
• Evolocumab and Saphenous Vein Graft Patency Following Coronary Artery Bypass Graft (CABG) Surgery in People with and without Diabetes: A Pre-Specified Analysis of the Randomized Placebo Controlled NEWTON-CABG CardioLink-5 Trial
• Effects of Real-Time Notification of AI-Derived Incidental Coronary Artery Calcium on Statin Initiation: the NOTIFY-PICTURE Trial *
• A Novel Approach to Manage Hypercholesterolemia: The Veterans Affairs Lipid Optimization Reimagined Quality Improvement (VALOR-QI) Program *
• Refining ASCVD Risk Stratification Using a Lipid-Derived Index: Multi-Cohort Evidence Beyond Guideline Thresholds

_{* Accepted, not confirmed}

Back to Top

LBBS.AOS.01 – Oral Abstract - Next-Generation Therapies for Ischemic Heart Repair: From Cells to Imaging

Sunday, Nov. 9, 2025, 8:00 – 9:15 AM

• First Demonstration of Significant and Durable Improvement of Cardiac Function in Pig Model of Ischemic Heart Failure with Direct Reprogramming Delivered Precisely to Infarct Border via Guided Intramyocardial Injection Catheter
• Clonal Hematopoiesis Associated with Trp53 and Dnmt3a Mutations Promotes Tissue Repair in Acute Cardiovascular Diseases
• Evaluating Precision Therapy Efficacy in Post-MI Cardiac Tissue Regeneration using Noninvasive Optoacoustic Imaging*
• Implantable Epicardial Cell-Based Platform for Localized Immunomodulation of Ischemic Myocardium
• Systemic Delivery of Angiopoietin-1 Derived Q-peptide Modulates the Fibroinflammatory Response to Improve Cardiac Function in a Rat Myocardial Infarction Model

LBBS.AOS.02 – Oral Abstract - Mechanisms Underlying Vascular Dysfunction

Monday, Nov. 10, 2025, 8:00 – 9:15 AM

• Endothelial AGO1 Drives Vascular Inflammation and Atherosclerosis *
• Hyperglycemia-Induced Collapse of 3D Genome Organization in Endothelial Cells Underlies Diabetic Vascular Disease *
• TEAD transcription factors are novel and essential regulators of vascular smooth muscle homeostasis
• Interrogating the cross-talk: Endothelial-Macrophage interactions in Diabetic Vascular Dysfunction
• Macrophage-specific deletion of Fortilin mitigates atherosclerosis by promoting apoptosis, suppressing lipid uptake, and shifting intimal cell composition *

LBBS.MDP.01-Moderated Digital Poster Session 1- Mechanisms and Treatments for Vascular Diseases

Saturday, Nov. 8, 10:45 AM – 12:00 PM

• Integrative Omics Analyses of Human Aortic Valves Identify Ceramide de novo Synthesis as a Novel Therapeutic Target to Mitigate Lipotoxicity and Subsequent Calcific Aortic Valve Disease *
• Neuropilin-1 Regulates Aortic Smooth Muscle Contractility and Is Required for Angiotensin II–Driven Hypertension *
• Surgical celiac ganglion sympathectomy attenuates atherosclerosis via expansion of atheroprotective NRP1+LYVE1+ macrophages *
• Prognostic Value of Serum Bilirubin and Therapeutic Potential of the Bilirubin-based Nanoparticle for Atherosclerotic Cardiovascular Disease*
• Fortilin Inhibits Differentiation of Macrophages and Mesenchymal Stem Cells To Vascular Smooth Muscle Cells
• Fortilin Deficiency Induces Anti-Atherosclerotic Phenotypes in Macrophages and Protects Hypercholesterolemic Mice Against Atherosclerosis
• Age Associated T cells (TAA cells) expressing Granzyme k are novel cell types in Atherosclerotic plaques
• Integrin–ER Stress Crosstalk Links Mechanical and Metabolic Stress to Vascular Inflammation *
• The RNA editor ADARB1 controls polyvascular disease by enhancing metabolic inflammation *

LBBS.MDP.02- Moderated Digital Poster Session 2- From Chromatin to Cytokines: Mechanistic Insights into Heart Failure

Sunday, Nov. 9, 3:15 – 4:30 PM

• Role of Histone Lysine Demethylase KDM5A in Lamin A/C Dilated Cardiomyopathy
• METTL3-Mediated m6A Methylation of FDX1 Regulates Cuproptosis in Myocardial Ischemia-Reperfusion Injury *
• Blocking ANTXR1 in Cardiac Fibroblasts Alleviates Heart Failure in Mice via the TGF-β Pathway *
• Adipocyte-Derived Small Extracellular Vesicles Enriched with NNMT Inhibit Angiogenesis Post-Myocardial Infarction in Diabetes *
• Dietary 7-ketocholesterol exacerbates post-myocardial infarction left ventricular remodeling in mice through macrophage-mediated inflammation
• Sustained VASH Inhibition in the ZSF1 Rat Model of HFpEF
• A dual-action prokaryotic sodium channel expression for electro-mechanical rescue in chronic heart failure
• Protein phosphatase 2A, a critical modulator of cardiomyocyte ferroptosis in takotsubo syndrome *
• Proteomic and transcriptomic signatures indicate a role in loss of Y chromosome for inflammaging in human heart failure *
• IL27 Exerts a Powerful Effect on Systolic Overload-Induced Cardiac Inflammation and Heart Failure Development Through Stimulating T Cells and Cardiomyoyctes *

LBBS.APS.01- Abstract Poster Board Session (Flat boards)- Precision Interventions for the Failing Heart: Genetic, Metabolic, and Immune Frontiers

Saturday, Nov. 8, 2:30 – 3:30 PM

• In vivo gene editing of Angiotensinogen in hepatocytes safely and potently reduces blood pressure in preclinical models
• Targeting Neuroinflammation After Cardiac Arrest Using Anti-Inflammatory Lipid Nanoparticles *>
• DNMT3B-Mediated Epigenetic Reprogramming Induces Cardiomyocyte Dedifferentiation and Proliferation, Enhancing Post-MI Cardiac Regeneration *
• Aortic Stenosis is Promoted by Ferroptosis via 5-Lipoxygenase
• Exosome-loaded with Small Cajal Body Associated RNA20: A Novel Therapeutic Strategy for Cardiovascular Disease *
• STAT3 increases endothelial-to-mesenchymal transition to promote vascular permeability in hypoxia-induced pulmonary hypertension *
• Danicamtiv, a Novel Direct Enhancer of Cardiac Myosin Motor Function, Improves Cardiac Performance and Output in the setting of Myosin Dysfunction: In vitro and In vivo Evidence *
• Salt-sensitive Hypertension Initiates with Intracellular K+ and Water Loss
• Renal Tissue Oxygenation Improves during Mechanical Circulatory Support in an Ovine Model of Ischemic Left Ventricular Systolic Dysfunction
• Single-cell and extracellular vesicle profiling reveals fibroblast-macrophage crosstalk in epicardial adipose tissue during acute myocardial infarction
• Lymphatic dysfunction and inflammatory lymphangiogenesis precede the onset of cardiac dysfunction in the hearts of the Duchenne Muscular Dystrophy (DMD) mouse model
• FAK Inhibition Attenuates Macrophage Foam Cell Formation by Disrupting CD36-Filamin A-dependent oxLDL Uptake *
• Tirzepatide Attenuates Diabetic Cardiomyopathy via Dual DUSP10 Upregulation and SRSF3 deNEDDylation to Reprogram Cardiac Metabolism *
• Metabolic Drug, Electrophysiological Savior: Unmasking GLP-1RA's Novel Therapeutic Target in Sinoatrial Node Dysfunction
• Closing The CHD Diagnostic Gap: AI-Enhanced Discovery of Disease-Causal Genetic Variants
• Targeting the CXCL10-IFN-γ Axis to Prevent Myocardial Injury Following mRNA Vaccination *
• Acute Hemodynamic Effects of Sotatercept in Pulmonary Arterial Hypertension *
• Transcatheter, Subvalvular Delivery of Millimeter-Scale, Self-Powered, Bioresorbable Pacemaker for Left Bundle Branch Pacing and Resynchronization Therapy *
• Augmentation of VIP signaling prevents the development of DMD-Associated Cardiomyopathy through inhibition of NF-κB signaling *
• A human cardiomyocyte model of CD36 haploinsufficiency uncovers fatty acid oxidation deficits driving dilated cardiomyopathy *
• ATOH8 drives fibrotic remodeling in the human heart as a molecular regulator – a single-cell based validation approach of a potential therapeutic target in cardiac fibrosis *
• Hydrogen Sulfide Donor Therapy Attenuates HFpEF by Regulating Myocardial Calcium Signaling and Cardiac Hypertrophy *
• A Highly Selective and Orally Available HDAC6 Inhibitor, EKZ-102, Ameliorates Cardiac Dysfunction and Exercise Intolerance in Cardiometabolic HFpEF *
• Early Systemic Immune Response After Cardiac Arrest and The Immunomodulatory and Neuroprotective Effects of LPC(22:6) *
• Preclinical Study of SEPRDD (sensing pressure and releasing Diuretic Drug) Heart Failure Device: Therapeutic Efficacy in a Goat Model *
• A mechanism whereby SGLT2 inhibitor dapagliflozin reverses cardiac diastolic dysfunction in a model of HFpEF
• First in class CRF2 receptor agonist COR-1167, reduces decompensation, improves exercise capacity, cardiac and renal function on top of Empagliflozin in the ZSF-1 rat model of worsening heart failure with preserved ejection fraction *
• Novel Combination Therapy with Sildenafil and Rapamycin Potentiates Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer while Suppressing its Cardiotoxicity *
• Preclinical Characterization of a Novel and Potent Antiplatelet Drug SBK019 *

_{* Accepted, not confirmed}

Back to Top

HF.ME.01 Forgotten No More: The Current Belle of the Ball? Breakthrough Evolutions in Hypertrophic Cardiomyopathy

Saturday, November 08, 2025, 9:45 AM

• TN-201 MyPEAK – TN-201, an Investigational MYBPC3 Gene Replacement Therapy: Interim Clinical Data from MyPEAK-1, a Phase Ib/2a Study Evaluating Safety and Early Efficacy of TN-201 in Adult Patients with MYBPC3-Associated Hypertrophic Cardiomyopathy

PL.ME.02 Shifting Paradigms in Lipid Management for ASCVD Risk

Saturday, November 08, 2025, 1:30 PM

• CORALreef Lipids – Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, for Lowering LDL Cholesterol in Adults with or At-Risk for ASCVD: The Phase 3 CORALreef Lipids Trial *

Other ways to view Late-Breaking Science

IntSym.02 Circulating Global Health Knowledge: Key Findings from AHA Journals

Friday, November 07, 2025, 2:00 PM

• Worldwide Patterns for Premature Atherosclerotic Cardiovascular Disease: A Meta-Analysis.

IntSym.03 Advances in Global Health Research: Opportunities and Challenges

Friday, November 07, 2025, 4:00 pm

• Deep learning derived coronary artery calcium from retinal images for prediction of cardiovascular disease in two different cohorts: Multi-Ethnic Study of Atherosclerosis (MESA) and Rotterdam Study (MERO)
• Contrasting the haemodynamic profile versus health service burden of 1.2 million men and women with aortic stenosis (2010-21): New insights from the National Echo Database of Australia

PL.CVS.08 The AHA Health Care by Food Initiative is Bearing Fruits: Early Results from the AHA Food is Medicine Pilot Projects

Monday, November 10, 2025, 3:15 PM

• A Clinical Trial of Healthy Food Subsidies and Behavioral Interventions to Increase Fruit and Vegetable Purchasing in an Online Store*

_{* Accepted, not confirmed}

Back to Top